Alkermes is chasing Takeda Pharmaceutical, whose orexin receptor-targeting pill is on track to become first in a new class of narcolepsy medicines. Blair Jackson, chief operating officer of the neuroscience biotech, says Alkermes’s drug offers advantages and also paves the way to bring orexin agonism to other indications.
The post Neuroscience Biotech Alkermes Sees Narcolepsy R&D as Launchpad for a Range of New Fatigue Therapies appeared first on MedCity News.
